Greenland Mines Hosts Briefing on Mining and Biotech Projects

In a bold strategic shift, Klotho Neurosciences has officially rebranded as Greenland Mines Ltd (Nasdaq: GRML).

Based in Charlotte, North Carolina, the company has adopted a unique dual-business model that combines high-tech gene therapy with Arctic natural resource exploration.

While continuing to advance its KLTO-202 therapy candidate for Amyotrophic Lateral Sclerosis (ALS), the company is aggressively pursuing the Skaergaard Project in southeast Greenland.

To ensure environmental compliance, the company is conducting multi-year biological surveys and has joined the Greenland Business Association to foster local economic ties.

Despite this massive potential, the company faces significant hurdles, including Nasdaq compliance challenges regarding its minimum bid price.

By diversifying into mining, Greenland Mines aims to stabilize its risk profile and attract a broader range of investors, creating an unlikely synergy between medical innovation and heavy industry as it works toward a sustainable future in the Arctic.